Yet another company developing a drug for Duchenne muscular dystrophy suffered a setback as PTC Therapeutics disclosed yesterday that the Food and Drug Administration rejected its application for its experimental treatment.
Read Full Article »
FDA Rejects Application for Duchenne Drug
Comment
